Bijsterveld NR. Moons AH. Boekholdt SM. van Aken BE. Fennema H. Peters RJ. Meijers JC. Buller HR. Levi M., Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation. 106(20):2550-4, 2002
The newer anticoagulant fondaparinux is increasingly being used in the postoperative prevention of venous thrombosis. Because any anticoagulant therapy poses a risk of bleeding complications; a strategy to reverse the effects of fondaparinux is desirable. The objective of this study was to investigate whether recombinant factor VIIa (rFVIIa) could neutralize the anticoagulant effects of subcutaneously administered fondaparinux. In a randomized, placebo-controlled design, 16 healthy male subjects received either a single subcutaneous dose of fondaparinux (10 mg) and a single intravenous bolus of rFVIIa (90 micrograms/kg; n=8), fondaparinux and placebo (n=4), or placebo and rFVIIa (n=4). Fondaparinux (or placebo) was administered 2 hours before rFVIIa (or placebo). Injection of rFVIIa after fondaparinux normalized the prolonged activated partial thromboplastin and prothrombin times and reversed the decrease in prothrombin activation fragments 1+2 (F(1+2)), as observed with fondaparinux alone. Thrombin-generation time and endogenous thrombin potential, which were inhibited by fondaparinux, normalized up to 6 hours after rFVIIa injection. The authors conclude that rFVIIa is capable of normalizing coagulation times and thrombin generation during fondaparinux treatment. The duration of this effect ranged from 2 to 6 hours after rFVIIa injection. These results suggest that rFVIIa may be useful to reverse the anticoagulant effect of fondaparinux in case of serious bleeding complications or need for acute surgery during treatment with fondaparinux.
Prescribing Info - Questions - Drug Info - Links - PDA Software - Article Summaries - Slideshows - Review Articles - What's New
© Copyright 1999-2020 All Rights Reserved.